Deciphera Pharmaceuticals (NASDAQ:DCPH) Upgraded to “Equal Weight” at Barclays

Barclays upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from an underweight rating to an equal weight rating in a research report released on Tuesday morning, Benzinga reports. Barclays currently has $26.00 price target on the stock, up from their previous price target of $9.00.

A number of other analysts have also issued reports on the stock. Jonestrading restated a hold rating and issued a $25.60 price target on shares of Deciphera Pharmaceuticals in a research note on Monday. Stifel Nicolaus lifted their price objective on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a buy rating in a report on Wednesday, February 7th. Jefferies Financial Group reaffirmed a hold rating and issued a $25.60 price objective (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a neutral rating in a report on Wednesday, March 20th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Hold and an average price target of $24.17.

Deciphera Pharmaceuticals Trading Down 0.0 %

Shares of NASDAQ:DCPH opened at $25.27 on Tuesday. The company has a fifty day simple moving average of $15.98 and a 200 day simple moving average of $14.55. The firm has a market cap of $2.08 billion, a PE ratio of -11.03 and a beta of 0.39. Deciphera Pharmaceuticals has a 12-month low of $9.90 and a 12-month high of $25.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The business’s revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.60) earnings per share. As a group, equities research analysts forecast that Deciphera Pharmaceuticals will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Deciphera Pharmaceuticals by 67.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 15,513 shares of the company’s stock valued at $244,000 after acquiring an additional 6,241 shares during the period. Diversified Trust Co boosted its holdings in shares of Deciphera Pharmaceuticals by 6.5% during the first quarter. Diversified Trust Co now owns 12,747 shares of the company’s stock valued at $201,000 after acquiring an additional 778 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at $291,000. Fisher Asset Management LLC acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter valued at $1,006,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Deciphera Pharmaceuticals by 14.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after acquiring an additional 290,968 shares during the period. Institutional investors and hedge funds own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.